Over-the-Counter Drugs Market Growth And Future
Outlook By 2026
Over-the-counter drugs, also known as non-prescription drugs, are available in pharmacies and
other retail stores and can be used without being prescribed by a doctor. These drugs are
critical components of the pharmaceutical industry as they are highly potent and have the
capability to show effective results for simple diseases. The number of competitors diving into
the large pool of pharmaceutical industry are increasing day-by-day making the industry a
promising venture for new comers to capitalize upon. This review will help to attain a
competitive analysis of developments such as strategic alliances, mergers and acquisition, joint
ventures as well research and innovation leading to product development with respect to over-
the-counter drugs market. According to Consumer Healthcare Products Association, the total
U.S. sales for OTC medicines accounted for US$ 34,327 million in 2017.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1443
Competitive Analysis - The top 10 players operating in the global over-the-counter drugs market
include:
1. Pfizer, Inc. - Pfizer, Inc. is a global leading manufacturer and distributor of over-the-
counter drugs, managing its commercial operation through two major business segments
namely, Pfizer Innovative Health and Pfizer Essential Health. OTC drugs contribute to a
major part of Innovative Health Segment, comprising annual revenue of US$ 29,197
million in 2016. The company OTC drugs portfolio includes over 40 products, whereas
the leading OTC brands that generated significant revenue for Pfizer included Advil
(Ibuprofen capsules for migraine) and Centrum (Multivitamin Tablets), in 2016. Moreover,
the company collaborated for the license of Nexium OTC rights under the exclusive
agreement with AstraZeneca Plc made in 2012, Pfizer paid US$ 93 Mn to AstraZeneca in
April, 2016 as accrued milestone payments as per the norms of the agreement. Pfizer,
Inc. adopts strategies such as entering into partnerships and collaborations with
companies that adopts incorporation of novel, proprietary drug-delivery technologies as